The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Emerging novel targeted therapies in pancreatic cancer
Davide Melisi, MD, PhD, University of Verona, Verona, Italy, provides an overview promising new therapeutic approaches for pancreatic cancer. Key advancements include KRAS inhibitors, targeting both allele-specific and pan-RAS mutations, which are critical due to the high mutation rate of this oncogene in pancreatic cancer. Agents modulating the immune and stromal microenvironment, such as CD40 agonists and adenosine pathway inhibitors, show potential in enhancing immune response. Synthetic lethality strategies, particularly targeting MTAP loss with PRMT5 inhibitors, and the use of PARP inhibitors in BRCA-mutated tumors combined with immune checkpoint inhibitors, also hold significant promise. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
